Pharmacogenetics to predict drug-related adverse events.


Journal Article (Review)

Identification of reliable markers to predict drug-related adverse events (DRAEs) is an important goal of the pharmaceutical industry and others within the healthcare community. We have used genetic polymorphisms, including the most frequent source of variation (single nucleotide polymorphisms, SNPs) in the human genome, in pharmacogenetic approaches designed to predict DRAEs. Three studies exemplify the principles of using polymorphisms to identify associations in progressively larger genomic regions: polymorphic repeats within the UDP-glucuronysltransferase I (UGT1A1) gene in patients experiencing hyperbilirubinemia after administration of tranilast, an experimental drug to prevent re-stenosis following coronary revascularization; high linkage disequilibrium within the Apolipoprotein E (ApoE) gene in patients with Alzheimer Disease (AD); and the polymorphic variant HLA-B57 in patients with hypersensitivity reaction after administration of abacavir, a nucleoside reverse transcriptase inhibitor for the treatment of HIV. Together, these studies demonstrate in a stepwise manner the feasibility of using pharmacogenetic approaches to predict DRAEs.

Full Text

Cited Authors

  • Hosford, DA; Lai, EH; Riley, JH; Xu, C-F; Danoff, TM; Roses, AD

Published Date

  • March 2004

Published In

Volume / Issue

  • 32 Suppl 1 /

Start / End Page

  • 9 - 12

PubMed ID

  • 15209398

Pubmed Central ID

  • 15209398

Electronic International Standard Serial Number (EISSN)

  • 1533-1601

International Standard Serial Number (ISSN)

  • 0192-6233

Digital Object Identifier (DOI)

  • 10.1080/01926230490424743


  • eng